Without knowing the mandates of the funds I would have thought...

First 51 Last

Share
Profile

Follow
cptcaveman

653 Posts.

3

13/02/15

17:27

Post #: 14752480
Share

Originally posted by Ocker ↑

A second half dividend of 9.5c is far from a given because that assumes NPAT for the period will be roughly the same as the pcp. Whilst a nice thought I do think the reality is that there is no chance whatsoever.

The resource sector is still reducing their contract labour force and whilst that probably had a minimal effect on the first half, a far greater impact will hit SKE in the second. To what degree we will find out in time. What concerns me most is the fact SKE did not provide any forward guidance in terms of NPAT for second half.

Taking a pessimistic assessment, if they cut the second half to 4c that would give a current full year of 11.5c or about 8.2%. However, looking forward to 2015/2016, reduce the first half to 3.5c and leave second half at 4c, you end up with 7.5c or 5.5%. One cannot just look at this year, rather you need to look beyond 2014/2015 as that is the the fund managers do.

Put another way, if the prospects are for a full year dividend of 17c, and the same going forward then professional investors (funds etc) would be all over SKE like a rash

Expand

Without knowing the mandates of the funds I would have thought that a fully franked 5.5% in dividends would still pique their interest.

Alas, my thoughts will only be confirmed when we hopefully contract that rash sometime in the future.

Has anyone got analysts workings post 1H results that they can share? Would be interesting to see how bearish they are, if at all, or whether they opting for more favourable forecasts based on recent earnings history.

SKE Price at posting: $1.37 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech bounces back from FDA rejection with new baseline study for NTI164

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 51 more messages in this thread...

First 51 Last

Add SKE (ASX) to my watchlist

Without knowing the mandates of the funds I would have thought...

Top Stories

Neurotech bounces back from FDA rejection with new baseline study for NTI164

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Featured News